Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EXOZ NASDAQ:KMDA NASDAQ:PRTC NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXOZeXoZymes$12.50+0.8%$10.10$8.50▼$23.99$104.88MN/A13,673 shs703 shsKMDAKamada$6.83-2.7%$7.33$5.17▼$9.15$393.10M0.89124,402 shs48,302 shsPRTCPureTech Health$16.06-0.1%$17.97$13.30▼$24.99$387.54M1.114,540 shs1,870 shsSLDBSolid Biosciences$5.59+3.6%$5.95$2.41▼$8.10$434.90M2.541.81 million shs463,656 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXOZeXoZymes0.00%+3.68%+27.84%-2.29%+1,239,999,900.00%KMDAKamada0.00%-1.68%-4.49%-1.82%+28.57%PRTCPureTech Health0.00%-3.28%-16.14%-18.76%-19.47%SLDBSolid Biosciences0.00%-2.00%-11.78%+7.37%-32.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXOZeXoZymes$12.50+0.8%$10.10$8.50▼$23.99$104.88MN/A13,673 shs703 shsKMDAKamada$6.83-2.7%$7.33$5.17▼$9.15$393.10M0.89124,402 shs48,302 shsPRTCPureTech Health$16.06-0.1%$17.97$13.30▼$24.99$387.54M1.114,540 shs1,870 shsSLDBSolid Biosciences$5.59+3.6%$5.95$2.41▼$8.10$434.90M2.541.81 million shs463,656 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXOZeXoZymes0.00%+3.68%+27.84%-2.29%+1,239,999,900.00%KMDAKamada0.00%-1.68%-4.49%-1.82%+28.57%PRTCPureTech Health0.00%-3.28%-16.14%-18.76%-19.47%SLDBSolid Biosciences0.00%-2.00%-11.78%+7.37%-32.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXOZeXoZymes 0.00N/AN/AN/AKMDAKamada 2.67Moderate Buy$13.0090.31% UpsidePRTCPureTech Health 0.00N/AN/AN/ASLDBSolid Biosciences 3.09Buy$15.00168.58% UpsideCurrent Analyst Ratings BreakdownLatest EXOZ, KMDA, SLDB, and PRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/14/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$15.00 ➝ $13.008/13/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $14.007/21/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$16.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXOZeXoZymes$70K1,498.21N/AN/A$1.25 per share10.00KMDAKamada$169.52M2.32$0.48 per share14.28$4.51 per share1.51PRTCPureTech Health$6.17M62.85$2.38 per share6.74$17.04 per share0.94SLDBSolid Biosciences$8.09M53.76N/AN/A$3.43 per share1.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXOZeXoZymes-$5.86MN/A0.00∞N/AN/A-134.50%-81.63%N/AKMDAKamada$14.46M$0.3420.1121.350.7511.22%7.41%5.18%11/12/2025 (Estimated)PRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/AN/ASLDBSolid Biosciences-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)Latest EXOZ, KMDA, SLDB, and PRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025KMDAKamada$0.09$0.13+$0.04$0.13$158.59 million$44.75 million8/12/2025Q2 2025EXOZeXoZymesN/A-$0.28N/A-$0.28N/AN/A8/12/2025Q2 2025SLDBSolid Biosciences-$0.51-$0.42+$0.09-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXOZeXoZymesN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXOZeXoZymes0.016.196.19KMDAKamadaN/A4.002.21PRTCPureTech HealthN/A8.499.33SLDBSolid BiosciencesN/A9.349.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXOZeXoZymesN/AKMDAKamada20.38%PRTCPureTech Health0.04%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipEXOZeXoZymes72.41%KMDAKamada36.10%PRTCPureTech Health5.30%SLDBSolid Biosciences13.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXOZeXoZymes298.39 million2.31 millionN/AKMDAKamada36057.51 million36.75 millionOptionablePRTCPureTech Health10024.13 million22.89 millionNot OptionableSLDBSolid Biosciences10077.87 million67.26 millionOptionableEXOZ, KMDA, SLDB, and PRTC HeadlinesRecent News About These CompaniesWall Street Zen Downgrades Solid Biosciences (NASDAQ:SLDB) to SellSeptember 15 at 2:43 AM | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Stock Rating Lowered by Wall Street ZenSeptember 15 at 2:55 AM | marketbeat.comSiren L.L.C. Has $27.44 Million Holdings in Solid Biosciences Inc. $SLDBSeptember 13 at 3:12 AM | marketbeat.comSolid Biosciences Inc. $SLDB Shares Acquired by Alyeska Investment Group L.P.September 8, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Grows Stock Holdings in Solid Biosciences Inc. $SLDBSeptember 7, 2025 | marketbeat.comWalleye Capital LLC Has $204,000 Holdings in Solid Biosciences Inc. $SLDBSeptember 7, 2025 | marketbeat.comBrokerages Set Solid Biosciences Inc. (NASDAQ:SLDB) Price Target at $15.00September 7, 2025 | americanbankingnews.comEcoR1 Capital LLC Purchases New Stake in Solid Biosciences Inc. $SLDBSeptember 6, 2025 | marketbeat.comJump Financial LLC Acquires New Position in Solid Biosciences Inc. $SLDBSeptember 6, 2025 | marketbeat.comSolid Biosciences Inc. $SLDB is Bain Capital Life Sciences Investors LLC's 7th Largest PositionSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Cuts Stake in Solid Biosciences Inc. $SLDBSeptember 5, 2025 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comRedmile Group LLC Has $7.47 Million Stock Position in Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comVestal Point Capital LP Sells 1,096,442 Shares of Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comBirchview Capital LP Makes New Investment in Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Invests $6.08 Million in Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comNantahala Capital Management LLC Takes Position in Solid Biosciences Inc. $SLDBSeptember 3, 2025 | marketbeat.comSolid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comApis Capital Advisors LLC Purchases Shares of 110,000 Solid Biosciences Inc. $SLDBSeptember 2, 2025 | marketbeat.comSolid Biosciences to Participate at Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comResolute Capital Asset Partners LLC Makes New $555,000 Investment in Solid Biosciences Inc. $SLDBAugust 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEXOZ, KMDA, SLDB, and PRTC Company DescriptionseXoZymes NASDAQ:EXOZ$12.50 +0.10 (+0.81%) As of 09:52 AM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Kamada NASDAQ:KMDA$6.83 -0.19 (-2.69%) As of 03:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.PureTech Health NASDAQ:PRTC$16.06 -0.02 (-0.13%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Solid Biosciences NASDAQ:SLDB$5.58 +0.20 (+3.62%) As of 03:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
